Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study

Autor: José Antonio Pinto, Alex Fonollosa, Ester Carreño, Maria Isabel Rodriguez, David Diaz-Valle, Diana Peiteado, Luis Rodriguez-Rodriguez, Miguel Cordero-Coma, Marta Tejera Santana, Lidia Cocho, Ana Belen Rivas, Amanda Lopez-Picado, Valentina Calamia, Felix M Francisco Hernandez, Angel Garcia-Aparicio, Javier Garcia-Gonzalez, Jose Juan Mondejar, Leticia Lojo-Oliveira, Llucí Martínez-Costa, Santiago Munoz, Beatriz Rodriguez-Lozano, Esperanza Pato, Elena Molina, Luis Alberto Tebar, Mara Albert Fort, Mayte Ariño Gutierrez, Pedro Arriola Villalobos, Joseba Artaraz Beobide, Antonio Atanes Sandoval, Jose Manuel Sanchez, Francisco Blázquez, Pablo Borges Deniz, Lara Borrego Sanz, Gabriela Bustamante Sanchez-Arnedo, Bruno Casco Silva, Ricardo Cuiña Sardiña, Almudena De Pablo Cabrera, Maria Del Mar Esteban Ortega, Patricia Fernandez Puente, Dalifer Dayanira Nuñez, Javier Garcia Bella, Sara Garcia Carazo, Luis Garcia Onrubia, Jose Maria Morales, Jose Antonio Fernandez, Vanesa Hernandez Hernandez, Inés Hernanz Rodriguez, Jose Maria Cantalapiedra, Ventura Hidalgo Barrero, Maria De Jovani Casano, Sara López Sierra, Virginia Lozano Lopez, Alfredo Madrid Garcia, Rosalia Mendez Fernandez, Pilar Nozal Aranda, Eugenio Perez Blazquez, Chamaida Plasencia Rodriguez, Sheila Recuero Diaz, Ignacio Robles Barrena, Esther Rodriguez Almaraz, Fayna Maria Gonzalez, Guadalupe Rodriguez Martinez, Fredeswinda Isabel Bueno, Ioana Ruiz Arruza, Beatriz Sanchez Marugan, Olga Sanchez Pernaute, Armelle Schlinker Giraud, Alvaro Seijas Lopez, Patricia Simon Alonso, Elia Valls Pascual

Publikováno v: BMJ Open, Vol 12, Iss 3 (2022)

Introduction Non-infectious uveitis include a heterogeneous group of sight-threatening and incapacitating conditions. Their correct management sometimes requires the use of immunosuppressive drugs (ISDs), prescribed in monotherapy or in combination.

Externí odkaz: https://doaj.org/article/3d27a9e1d3f74fb69bbbda93ab9c84d7

Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results

Autor: Carlos Guijarro, Farid Zand, Mohamed solyman Kabil, Sven Trelle, Birgitte Tholin, Belén Comeche, Johan Alexander Azañero Haro, Gonzalo Sierra Torres, Quarraisha Abdool Karim, Kari Tikkinen, Jean-michel Molina, Atousa Hakamifard, George M Varghese, Oscar Josue Ponce Ponte, Mazin Barry, Pilar Vizcarra, Niccolo Riccardi, Natalia Pérez-Macias, Aynaa AlSharidi, Nelson Lee, Alexandra Binnie, Firouzé BANI-SADR, Beatriz Díaz-Pollán, Aldo Pietro Maggioni, Ilkka Kalliala, Florian Desgranges, Anders Benjamin Kildal, Katerina Nezvalova-Henriksen, Corinne Merle, Andrés Martín Alcántara, Benjamin Gaborit, Daniel Lozano Martín, Antonio Ramos-Martinez, Miguel Villegas-Chiroque, Fredy Orlando Guevara Pulido, Ana Fernández-Cruz, Cormac McCarthy, Thesla Palanee-Phillips, Annalisa Marinosci, Abdullah Assiri, Florent Wallet, Juan Pablo Balbuena, Avik Ray, Francesc Puchades, Rajarao Mesipogu, Marjatta Sinisalo, Jonathan Sterne, Antonio Portolés, Heike Cappel-Porter, Jussi Mustonen, Jeremy Nel, BRUNO MOURVILLIER, María Consuelo Miranda Montoya, Chiara Fanciulli, L Marjukka Myllärniemi, Edinson Dante Meregildo Rodriguez, Alexy Inciarte, Mohamed Hassany, François Danion, Elena Muñez Rubio, Jean-Pierre QUENOT, Esperanza Merino de Lucas, Sheela Godbole, Luis Guillermo Barreto Rocchetti, Katerina Spasovska, William Connors, Kiana Shirani, Umang Agrawal, Srinivas Murthy, Bjorn Blomberg, Vasee Moorthy, Amith Balachandran, Antonio De Pablo Esteban, Mahnaz Amini, Dag Arne Lihaug Hoff, Zeinab Siami, Guillaume Martin-Blondel, Heng Gee Lee, Thrilok Chander Bingi, Vijay Krishnan, ANA BELEN RIVAS PATERNA, Eric D'Ortenzio, Samy Zaky, Carlos Arturo Alvarez-Moreno, Alonso Soto, VIKAS MARWAH, Marco Tulio Medina, Zaira R. Palacios-Baena, Jean-Sébastien Hulot, Miguel Angel Hueda Zavaleta, Felipe García, Francisco Fanjul

Publikováno v: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2021, 384 (6), pp.497-511. ⟨10.1056/NEJMoa2023184⟩
Pan, Hongchao; Peto, Richard; Henao-Restrepo, Ana-Maria; Preziosi, Marie-Pierre; Sathiyamoorthy, Vasee; Abdool Karim, Quarraisha; Alejandria, Marissa M; Hernández García, César; Kieny, Marie-Paule; Malekzadeh, Reza; Murthy, Srinivas; Reddy, K Srinath; Roses Periago, Mirta; Abi Hanna, Pierre; Ader, Florence; Al-Bader, Abdullah M; Alhasawi, Almonther; Allum, Emma; Alotaibi, Athari; Alvarez-Moreno, Carlos A; ... (2021). Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results. New England journal of medicine NEJM, 384(6), pp. 497-511. Massachusetts Medical Society MMS 10.1056/NEJMoa2023184
The New England journal of medicine, Vol. 384, no.6, p. 497-511 (2021)
2020, ' Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results ', New England Journal of Medicine . https://doi.org/10.1056/NEJMoa2023184

The authors report interim results of the WHO Solidarity trial of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with Covid-19. Effects on overall mortality, initiation o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16340988d9937ca8ef93ad35262d9e60
https://hdl.handle.net/20.500.12866/9103